- Home
- TPST vs CING Comparison
TPST vs CING Comparison
Compare TPST & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- CING
- Stock Information
- Founded
- TPST 2011
- CING 2012
- Country
- TPST United States
- CING United States
- Employees
- TPST N/A
- CING N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- CING Health Care
- Exchange
- TPST Nasdaq
- CING Nasdaq
- Market Cap
- TPST 33.0M
- CING 26.7M
- IPO Year
- TPST N/A
- CING 2021
- Fundamental
- Price
- TPST $10.16
- CING $4.16
- Analyst Decision
- TPST Hold
- CING Strong Buy
- Analyst Count
- TPST 3
- CING 4
- Target Price
- TPST $30.00
- CING $30.67
- AVG Volume (30 Days)
- TPST 111.5K
- CING 160.0K
- Earning Date
- TPST 08-11-2025
- CING 08-26-2025
- Dividend Yield
- TPST N/A
- CING N/A
- EPS Growth
- TPST N/A
- CING N/A
- EPS
- TPST N/A
- CING N/A
- Revenue
- TPST N/A
- CING N/A
- Revenue This Year
- TPST N/A
- CING N/A
- Revenue Next Year
- TPST N/A
- CING N/A
- P/E Ratio
- TPST N/A
- CING N/A
- Revenue Growth
- TPST N/A
- CING N/A
- 52 Week Low
- TPST $5.35
- CING $3.02
- 52 Week High
- TPST $20.67
- CING $16.15
- Technical
- Relative Strength Index (RSI)
- TPST 72.60
- CING 42.84
- Support Level
- TPST $6.96
- CING $3.50
- Resistance Level
- TPST $10.90
- CING $4.31
- Average True Range (ATR)
- TPST 0.63
- CING 0.44
- MACD
- TPST 0.33
- CING -0.13
- Stochastic Oscillator
- TPST 81.24
- CING 29.46
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.